| Source: |
| Type: |
| The effectiveness of chemotherapy by increasing cancer cell sensitivity to the drugs used to treat them, which is known as “chemo-sensitization”. Chemo-Sensitizers: -Curcumin -Resveratrol -EGCG -Quercetin -Genistein -Berberine -Piperine: alkaloid from black pepper -Ginsenosides: active components of ginseng -Silymarin -Allicin -Lycopene -Ellagic acid -caffeic acid phenethyl ester -flavopiridol -oleandrin -ursolic acid -butein -betulinic acid |
| 4910- | Sal, | A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent |
| 5044- | SAS, | xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma |
| - | in-vitro, | Var, | NA |
| 4751- | Se, | Chemo, | Selenium Protects Against Toxicity Induced by Anticancer Drugs and Augments Antitumor Activity: A Highly Selective, New, and Novel Approach for the Treatment of Solid Tumors |
| - | in-vivo, | Var, | NA |
| 4725- | Se, | Targeting the Nrf2-Prx1 Pathway with Selenium to Enhance the Efficacy and Selectivity of Cancer Therapy |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HT29 |
| 4747- | Se, | Chemo, | antiOx, | Phase I trial of selenium plus chemotherapy in gynecologic cancers |
| - | Trial, | Ovarian, | NA |
| 4715- | Se, | The Interaction of Selenium with Chemotherapy and Radiation on Normal and Malignant Human Mononuclear Blood Cells |
| 4721- | SeNPs, | A review on selenium nanoparticles and their biomedical applications |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA | - | Review, | Arthritis, | NA |
| 4734- | SeNPs, | CPT-11, | Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles |
| - | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
| 4745- | SeNPs, | Chemo, | Translational Selenium Nanoparticles Promotes Clinical Non-small-cell Lung Cancer Chemotherapy via Activating Selenoprotein-driven Immune Manipulation |
| - | Study, | NSCLC, | NA |
| 4756- | SeNPs, | Selenium‐Containing Nanoparticles Combine the NK Cells Mediated Immunotherapy with Radiotherapy and Chemotherapy |
| 4608- | SeNPs, | Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics |
| - | Review, | Var, | NA | - | NA, | AD, | NA |
| 4504- | SeNPs, | Chit, | FA, | doxoR, | pH-responsive selenium nanoparticles stabilized by folate-chitosan delivering doxorubicin for overcoming drug-resistant cancer cells |
| - | in-vitro, | Var, | NA |
| 4469- | SeNPs, | Selenium Nanoparticles in Cancer Therapy: Unveiling Cytotoxic Mechanisms and Therapeutic Potential |
| - | Review, | Var, | NA |
| 3183- | SFN, | Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1 |
| - | in-vitro, | GBM, | NA |
| 2553- | SFN, | Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer |
| - | Review, | Bladder, | NA |
| 2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
| - | Review, | Bladder, | NA |
| 1730- | SFN, | Sulforaphane: An emergent anti-cancer stem cell agent |
| - | Review, | Var, | NA |
| 1731- | SFN, | Targeting cancer stem cells with sulforaphane, a dietary component from broccoli and broccoli sprouts |
| - | Review, | Var, | NA |
| 1722- | SFN, | Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems |
| - | Review, | Var, | NA |
| 1458- | SFN, | Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma |
| - | Review, | Bladder, | NA |
| 1436- | SFN, | PacT, | docx, | Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells |
| - | in-vivo, | BC, | SUM159 |
| 1434- | SFN, | GEM, | Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity |
| - | in-vitro, | CCA, | HuCCT1 | - | in-vitro, | CCA, | HuH28 | - | in-vivo, | NA, | NA |
| 1474- | SFN, | Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway |
| - | in-vitro, | Colon, | SW480 |
| 1484- | SFN, | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1481- | SFN, | docx, | Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 3326- | SIL, | Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B |
| 3300- | SIL, | Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy |
| - | Review, | Var, | NA |
| 1316- | SIL, | Chemo, | Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity |
| - | Analysis, | Var, | NA |
| 2418- | SK, | Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2 |
| - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 2196- | SK, | Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species |
| - | Review, | Var, | NA |
| 2184- | SK, | Cisplatin, | PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis |
| - | in-vitro, | CRC, | T24/HTB-9 |
| 2182- | SK, | Cisplatin, | Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 | - | in-vivo, | NA, | NA |
| 2227- | SK, | Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species |
| - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | GES-1 |
| 5102- | SK, | GEM, | Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway |
| 2008- | SK, | Cisplatin, | Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo |
| - | in-vitro, | CRC, | HCT116 | - | in-vivo, | NA, | NA |
| 1073- | SK, | Chemo, | Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 4891- | Sper, | Spermidine as a promising anticancer agent: Recent advances and newer insights on its molecular mechanisms |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1706- | SSE, | Selenium in Prostate Cancer: Prevention, Progression, and Treatment |
| - | Review, | Pca, | NA |
| 1688- | SSE, | Potential Role of Selenium in the Treatment of Cancer and Viral Infections |
| - | Review, | Var, | NA |
| 4739- | SSE, | Chemo, | Rad, | Therapeutic Benefits of Selenium in Hematological Malignancies |
| - | Review, | Var, | NA |
| 5078- | SSE, | Rad, | Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer |
| - | Trial, | Pca, | NA |
| 5073- | SSE, | Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study |
| - | Trial, | Var, | NA |
| 5084- | SSE, | GEM, | The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study |
| - | in-vitro, | PC, | PANC1 | - | vitro+vivo, | PC, | Panc02 |
| 5330- | TFdiG, | Cisplatin, | Theaflavin-3,3′-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | OVCAR-3 |
| 5222- | TQ, | Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB |
| - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 2124- | TQ, | Thymoquinone: an emerging natural drug with a wide range of medical applications |
| - | Review, | Var, | NA |
| 2122- | TQ, | Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer |
| - | Review, | Var, | NA |
| 2127- | TQ, | Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways |
| - | Review, | GBM, | NA |
| 2129- | TQ, | doxoR, | Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 2084- | TQ, | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1106 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid